For the latter two indications, medicines targeting the GLP-1R have delivered therapeutic benefits such as improved glycemic control and reduced body weight, with generally lower risk of hypoglycemia than has historically been observed with other antidiabetic treatments. The gene discussed is GLP1R; the disease is Hypoglycemia.